Computed tomography screening for lung cancer in Hodgkin's lymphoma survivors: decision analysis and cost-effectiveness analysis

Annals of Oncology ◽

10.1093/annonc/mdl023 ◽

2006 ◽

Vol 17 (5) ◽

pp. 785-793 ◽

Author(s):

P. Das ◽

A.K. Ng ◽

C.C. Earle ◽

P.M. Mauch ◽

K.M. Kuntz

Keyword(s):

Computed Tomography ◽

Lung Cancer ◽

Cost Effectiveness ◽

Decision Analysis ◽

Hodgkin’S Lymphoma ◽

Cost Effectiveness Analysis ◽

Hodgkin's Lymphoma ◽

Effectiveness Analysis ◽

Lymphoma Survivors

Download Full-text

IEV versus ESHAP for Treatment of the Patients with Relapsed/Refractory Hodgkin and Non-Hodgkin's Lymphoma in Iran: A Cost-Effectiveness Analysis

Chemotherapy Open access ◽

10.4172/2167-7700.1000217 ◽

2016 ◽

Vol 05 (04) ◽

Author(s):

Mostafa Habibian ◽

Mehdi dehghani

Keyword(s):

Cost Effectiveness ◽

Hodgkin’S Lymphoma ◽

Cost Effectiveness Analysis ◽

Hodgkin's Lymphoma ◽

Effectiveness Analysis ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma

Download Full-text

Cost-effectiveness analysis of febrile neutropenia (FN) prophylaxis with pegfilgrastim in non-Hodgkin's lymphoma (NHL) patients treated with chemotherapy in Spain: Table 1

European Journal of Hospital Pharmacy ◽

10.1136/ejhpharm-2012-000074.314 ◽

2012 ◽

Vol 19 (2) ◽

pp. 204.3-205

Author(s):

A. Dominguez-Gil ◽

A. Alegre ◽

A. Lopez ◽

I. Oyagüez ◽

L. Gutierrez ◽

...

Keyword(s):

Cost Effectiveness ◽

Febrile Neutropenia ◽

Hodgkin’S Lymphoma ◽

Cost Effectiveness Analysis ◽

Hodgkin's Lymphoma ◽

Effectiveness Analysis ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma

Download Full-text

COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA

PHARMACOECONOMICS Modern pharmacoeconomics and pharmacoepidemiology ◽

10.17749/2070-4909.2016.9.1.003-014 ◽

2016 ◽

Vol 9 (1) ◽

pp. 3-14 ◽

Author(s):

G. R. Khachatryan ◽

D. V. Fedyaev ◽

M. V. Avxentyeva ◽

V. S. Dombrovskiy

Keyword(s):

Cost Effectiveness ◽

Hodgkin’S Lymphoma ◽

Brentuximab Vedotin ◽

Cost Effectiveness Analysis ◽

Hodgkin's Lymphoma ◽

Effectiveness Analysis

Download Full-text

PCN175 - BRENTUXIMAB VEDOTIN COMPARED WITH STANDARD THERAPY FOR PATIENTS WITH ADVANCED-STAGE HODGKIN’S LYMPHOMA: A COST-EFFECTIVENESS ANALYSIS

Value in Health ◽

10.1016/j.jval.2018.09.258 ◽

2018 ◽

Vol 21 ◽

pp. S44

Author(s):

A. Raymakers ◽

S. Costa ◽

S.J. Peacock ◽

D. Regier

Keyword(s):

Cost Effectiveness ◽

Standard Therapy ◽

Hodgkin’S Lymphoma ◽

Brentuximab Vedotin ◽

Cost Effectiveness Analysis ◽

Hodgkin's Lymphoma ◽

Advanced Stage ◽

Effectiveness Analysis

Download Full-text

Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting

Lung Cancer ◽

10.1016/j.lungcan.2004.11.001 ◽

2005 ◽

Vol 48 (2) ◽

pp. 171-185 ◽

Author(s):

Renee Manser ◽

Andrew Dalton ◽

Rob Carter ◽

Graham Byrnes ◽

Mark Elwood ◽

...

Keyword(s):

Computed Tomography ◽

Lung Cancer ◽

Cost Effectiveness ◽

Low Dose ◽

Spiral Ct ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis

Download Full-text

Cost-Effectiveness Analysis of Brentuximab Vedotin in Adults with Relapsed or Refractory Hodgkin’s Lymphoma

Value in Health ◽

10.1016/j.jval.2016.09.2217 ◽

2016 ◽

Vol 19 (7) ◽

pp. A734 ◽

Author(s):

GR Khachatryan ◽

D Fedyaev ◽

M Avxentyeva ◽

VS Dombrovskiy

Keyword(s):

Cost Effectiveness ◽

Hodgkin’S Lymphoma ◽

Brentuximab Vedotin ◽

Cost Effectiveness Analysis ◽

Hodgkin's Lymphoma ◽

Effectiveness Analysis

Download Full-text

R-CHOP vs. CHOP: a cost-effectiveness analysis on agrresive non-Hodgkin's Lymphoma (NHL)

Management in Health ◽

10.5233/mih.2009.0013 ◽

2009 ◽

Vol XIII (3) ◽

pp. 18-21 ◽

Author(s):

Anca Lupu ◽

Ciprian-Paul Radu ◽

Bogdan Pana ◽

Cristina Kalfas

Keyword(s):

Cost Effectiveness ◽

Hodgkin’S Lymphoma ◽

Cost Effectiveness Analysis ◽

Hodgkin's Lymphoma ◽

Effectiveness Analysis ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma

Download Full-text

Validating an Indolent Non-Hodgkin’s Lymphoma (NHL) Cost-Effectiveness Analysis Model Using Two Software Tools: Key Implementation Considerations and Results

Value in Health ◽

10.1016/j.jval.2013.08.1635 ◽

2013 ◽

Vol 16 (7) ◽

pp. A589

Author(s):

E.A. Wehler ◽

S.P. Bilir ◽

D. Bertwistle ◽

V. Leyva ◽

J. Munakata

Keyword(s):

Cost Effectiveness ◽

Hodgkin’S Lymphoma ◽

Software Tools ◽

Cost Effectiveness Analysis ◽

Hodgkin's Lymphoma ◽

Analysis Model ◽

Effectiveness Analysis ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma

Download Full-text

Cost-Effectiveness Analysis of Bendamustine-Rituximab Treatment Compared with Fludarabine-Rituximab Treatment, in Patients with Indolent Non-Hodgkin’s Lymphoma in Panamá

Value in Health ◽

10.1016/j.jval.2014.03.484 ◽

2014 ◽

Vol 17 (3) ◽

pp. A83

Author(s):

Z. Desanvicente-Celis ◽

C.A. Obando ◽

E. Rodriguez ◽

L. Gonzalez ◽

D. Muschett

Keyword(s):

Cost Effectiveness ◽

Hodgkin’S Lymphoma ◽

Cost Effectiveness Analysis ◽

Hodgkin's Lymphoma ◽

Effectiveness Analysis ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma

Download Full-text

Low-Dose Chest Computed Tomography for Lung Cancer Screening Among Hodgkin Lymphoma Survivors: A Cost-Effectiveness Analysis

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2014.06.013 ◽

2014 ◽

Vol 90 (2) ◽

pp. 344-353 ◽

Author(s):

Daniel A. Wattson ◽

M.G. Myriam Hunink ◽

Pamela J. DiPiro ◽

Prajnan Das ◽

David C. Hodgson ◽

...

Keyword(s):

Computed Tomography ◽

Lung Cancer ◽

Cost Effectiveness ◽

Cancer Screening ◽

Hodgkin Lymphoma ◽

Low Dose ◽

Lung Cancer Screening ◽

Chest Computed Tomography ◽

Effectiveness Analysis ◽

Lymphoma Survivors

Download Full-text